Suppressive effects of specific cellular inhibitors on plasma clot contraction driven by activated iMKs. (A, left) Images of the iMK-containing macroscopic plasma clots after 90 minutes of contraction in the absence and presence of 2 and 100 μM of blebbistatin. (A, right) Averaged kinetic contraction curves of iMK-containing plasma clots in the absence (control) and presence of 2 and 100 μM blebbistatin (mean ± SD; n = 6-11). (B) The extent of contraction (left) and average contraction velocity (right) of iMK-containing plasma clots in the absence and presence of 2 μM, 10 μM, and 100 μM of blebbistatin. Results are presented as the median and IQR. Statistical significance tested using the Kruskal-Wallis test. (C-D) Complete abrogation of the iMK-induced clot contraction by 1 μM latrunculin A (C) (red curve) and 10 μg/mL abciximab (D) (blue curve). The corresponding photographic images show contracted (top) and uncontracted (bottom) clots after 2 hours of incubation in the absence (top) and presence (bottom) of the inhibitors. IQR, interquartile range; SD, standard deviation.